Protocol Status: PUBLISHED
Protocol:
Version: 2026.01
Effective Date:
Last Reviewed:
Medical Director Approval:
Clinical Note: This content reflects current GCEMS clinical guidelines as of the dates listed above. If content appears inconsistent with current policy, use the most recent approved guideline and notify leadership for correction.

Solu-medrol

(Methylprednisolone)

 

GCEMS Protocol:

 

  • Anaphylactic/Allergic Reaction
  • Pediatric Anaphylactic/Allergic Reaction
  • Reactive Airway Disease

 

Indications

 

  • Moderate to severe exacerbation of reactive airway disease
  • Allergic reactions

 

DOSAGE:

ADULT:

 

  • 125 MG IV/IO

 

PEDIATRIC:

 

  • 2 mg/kg IV/IO; maximum 125 mg

 

CONTRAINDICATIONS:

 

  • Known hypersensitivity

 

SIDE EFFECTS:

 

  • depression
  • gastrointestinal bleeding
  • prolonged wound healing
  • suppression of natural steroids
  • Arrhythmias